-
Mashup Score: 0Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion - 1 year(s) ago
Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion How will Caplacizumab help patients with TMAs? I will be discussing the diagnosis and treatment of pregnant women with a prior diagnosis of TMAs, or thrombotic microangiopathy. This i…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion - 1 year(s) ago
iFrame is not supported! Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion How will Caplacizumab help patients with TMAs? I will be discussing the diagnosis and treatment of pregnant women with a prior diagnosis of TMAs, or thromboti…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion - 1 year(s) ago
Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion How will Caplacizumab help patients with TMAs? I will be discussing the diagnosis and treatment of pregnant women with a prior diagnosis of TMAs, or thrombotic microangiopathy. This i…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Caplacizumab: TMA Camila Masias ASH 2022 Complement-Media... - 1 year(s) ago
Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate How will Caplacizumab help patients with TMAs? I will be discussing the clinical diagnosis and treatment of pregnant women with a prior diagnosis of TMAs or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy (TMA), specifically TTP and complement-mediated HRES are rare diseases,…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Caplacizumab: TMA Camila Masias ASH 2022 Complement-Media... - 1 year(s) ago
Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate How will Caplacizumab help patients with TMAs? I will be discussing the clinical diagnosis and treatment of pregnant women with a prior diagnosis of TMAs or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy (TMA), specifically TTP and complement-mediated HRES are rare diseases,…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Caplacizumab: TMA Camila Masias ASH 2022 Complement-Media... - 1 year(s) ago
iFrame is not supported! Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate How will Caplacizumab help patients with TMAs? I will be discussing the clinical diagnosis and treatment of pregnant women with a prior diagnosis of TMAs or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy (TMA), specifically TTP and complement-mediated…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura - 1 year(s) ago
Key Points. Caplacizumab reduces exacerbation and refractoriness in iTTP.As initial therapy, caplacizumab accelerates response and reduces the need for PEX and
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Caplacizumab Reduces Exacerbations and Refractoriness in Real-World iTTP | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination October 27, 2022 Treatment with caplacizumab was associated with significant reductions in exacerbations and refractoriness in a real-world immune thrombotic thrombocytopenic purpura (iTTP) population compared…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 6How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge - 2 year(s) ago
Cataland and colleagues describe a clinical approach to the follow-up of patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) following acut
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Modified Caplacizumab Dosing for iTTP Offers Cost Savings, More Individualized Therapy | ASH Clinical News | American Society of Hematology - 2 year(s) ago
Skip Nav Destination April 27, 2022 The extension of caplacizumab application intervals from daily to alternate-day dosing may be safely considered after three to four weeks of daily treatment in selected…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion - Pregnancy in Women with a History of TMA, what did this discussion reveal? @MiamiCancerInst #ASH22 #Caplacizumab #ThromboticMicroangiopathy Watch and Share the Video Here: https://t.co/2h5gxd0YDN https://t.co/dkY6gSd2ga